Iron deficiency in Taiwanese patients with heart failure and reduced ejection fraction.

Abstract

Iron deficiency (ID) is a common co-morbidity among patients with heart failure and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent of anemia. This study aimed to evaluate the prevalence and prognostic significance of ID in Taiwanese patients with HFrEF. We included HFrEF patients from two multicenter cohorts at different periods. The multivariate Cox regression analysis was applied to assess the risk of outcomes associated with ID, accounting for the varying risk of death. Of the 3,612 patients with HFrEF registered from 2013-2018, 665 (18.4%) had available baseline iron profile measurements. Of these, 290 (43.6%) were iron deficient; 20.2% had ID+/anemia+, 23.4% ID+/anemia-, 21.5% ID-/anemia+, and 34.9% ID-/anemia-. Regardless of anemia status, patients with coexisting ID had a higher risk than those without ID [all-cause mortality: 14.3 vs. 9.5 per 100 patient-years, adjusted hazard ratio (HR) 1.33, 95% confidence interval (CI) 0.96-1.85, p=0.091; cardiovascular mortality: 10.5 per 100 patient-years vs 6.1, adjusted HR 1.54 (95% CI 1.03-2.30, p= 0.037); cardiovascular mortality or first unplanned hospitalization for HF: 36.7 vs 19.7 per 100 patient-years, adjusted HR 1.57 (95% CI 1.22-2.01, p<0.001)]. Among patients eligible for treatment in the IRONMAN trial design (43.9%), parenteral iron therapy was estimated to reduce heart failure hospitalizations and cardiovascular deaths by 13.7 per 100 patient-years. Iron profiles were tested in less than one-fifth of the Taiwanese HFrEF cohort. ID was present in 43.6% of tested patients and was independently associated with poor prognosis in these patients.